Genetics and novel aspects of therapies in systemic lupus erythematosus

Relle, Manfred; Weinmann‐Menke, Julia; Scorletti, Eva; Cavagna, Lorenzo; Schwarting, Andreas

doi:10.1016/j.autrev.2015.07.003

Cited by 62 publications

(46 citation statements)

References 284 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 The genetic factors might be a cause of this disorder, 20,21 but there are a lot of factors that also might be contributed in. The factors include molecular mimicry, genetics, and epigenetics.…”

Section: Foxp3 + T Cells ± Sd (%)mentioning

confidence: 99%

FOXP3 Modulation of Quercetin-3-O-rhamnoside and its Impacts on Lupus Nephritis Mice

Indriyanti¹,

Soeroso²,

Khotib³

2018

JYP

View full text Add to dashboard Cite

Background: Quercetin-3-O-rhamnoside (QUE) has anti-inflammatory and anti-oxidative effects which probably beneficially used in lupus. Objective: This research was focused on analyzing the effects of QUE on FOXP3 modulation to result in an anti-inflammatory outcome in the kidney of severe lupus mice. Methods: This research used Pristane-induced female BALB/c lupus mice, and the biomarkers involved in were CD4 + CD25+ T reg cells, FOXP3 T cells, anti-Sm, IL-6, and histopathology assessment of the kidney of lupus mice. The QUE group was treated and compared to the negative control which received placebo, and the positive control which received cyclophosphamide. Results: QUE increased the number of CD4 + CD25 + T reg cells (negative control: 3.01±3.43%; QUE: 18.77±5.12%; positive control: 3.26±11.09%), and FOXP3 significantly (p<0.05) (negative control: 1.14±0.54%; QUE: 2.00±1.45%; positive control: 1.73±1.14%). The antiSm level did not decrease, meanwhile the IL-6 decreased significantly, and the histopathological assessment of the kidney reveal the repairing effects of QUE on glomeruli. Conclusion: QUE has an anti-inflammatory activity which reduces the severity of lupus nephritis signs in lupus mice by initially increasing the CD4 + CD25+ and FOXP3 + Tregs numbers. QUE is potential to be further developed as a safe treatment choice for lupus nephritis. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

show abstract

Section: Foxp3 + T Cells ± Sd (%)mentioning

confidence: 99%

FOXP3 Modulation of Quercetin-3-O-rhamnoside and its Impacts on Lupus Nephritis Mice

Indriyanti¹,

Soeroso²,

Khotib³

2018

JYP

View full text Add to dashboard Cite

show abstract

“…-During rating rounds by the EG, a proposal was considered: o Appropriate / non-appropriate (strong agreement):  if the median response was ≥7 AND the response distribution was [7][8][9], the recommendation may be accepted as such, without the need for a second round of scoring;  if the median was ≤3 AND response distribution was [1][2][3], the recommendation was rejected as such. o Relative agreement / uncertain (indecision / no consensus):…”

Section: Detailed Process Of Response Analysismentioning

confidence: 99%

“…Poorly controlled disease drives a vicious circle, with organ damage undermining the longterm prognosis (1)(2)(3), triggered itself by persistent disease activity and particularly by corticosteroids abuse (4)(5)(6)(7)(8)(9)(10). Hence, the main target in clinical practice is to prevent damage and maintain stable disease control with limited doses of corticosteroids (7,11) An evidence-based approach to therapy is desirable, but the actual benefit demonstrated by randomized controlled trials and cohort evaluations of biologics in SLE are still limited (10,12). Only one biologic, belimumab (13), has been approved to date, but other biologics are sometimes used offlabel.…”

Section: Introductionmentioning

confidence: 99%

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus

Kleinmann

Tubach

Guern

et al. 2017

Autoimmunity Reviews

View full text Add to dashboard Cite

show abstract

“…The association rates shown in twin studies and prevalence results in first-degree/ second-degree relatives indicated a significant role of genetics in the occurrence of SLE (31,32). It is thought that polymorphisms in the FCGR2A, -2B, -3A and -3B genes encoding Fc gamma receptors, which are known to have a significant role in occurrence of the immune response, may be associated with SLE (33). The R620W variation in the 14 th exon on the PTPN22 gene has also been associated with a risk for SLE as well as with many autoimmune diseases (34).…”

Section: Known Susceptibility Genes In Commonly Observed Diseases Witmentioning

confidence: 99%

Role of genetics in pediatric rheumatology

et al. 2017

View full text Add to dashboard Cite

Pediatric rheumatology includes autoinflammatory monogenic diseases, autoinflammatory multifactorial diseases with complex inheritance, and diseases with uncertain clinical diagnosis or undefined conditions, even though they show signs of autoinflammation. Most of these diseases are systemic; it is important to diagnose patients promptly and definitively and to select proper treatment options based on the diagnoses. Clinical observation and acute-phase responses are usually sufficient for diagnosis; however, genetic analyses can provide supportive data for definite diagnosis and treatment, especially for rare monogenic diseases. As for multifactorial autoinflammatory diseases, susceptibility genes, and factors involved in the etiopathogenesis have not been fully identified. It is possible to identify disease genes and novel diseases, and lead to new treatment options by gene mapping studies and high-throughput screening strategies for multifactorial diseases and conditions with uncertain clinical characteristics. In this review, we discuss the three groups of autoinflammatory diseases and role of genetics in their diagnosis.

show abstract

Genetics and novel aspects of therapies in systemic lupus erythematosus

Cited by 62 publications

References 284 publications

FOXP3 Modulation of Quercetin-3-O-rhamnoside and its Impacts on Lupus Nephritis Mice

FOXP3 Modulation of Quercetin-3-O-rhamnoside and its Impacts on Lupus Nephritis Mice

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus

Role of genetics in pediatric rheumatology

Contact Info

Product

Resources

About